March 26, 2015 09:47 ET

DIAGNOS Announces Two Year Renewal of Successful Program in the UAE

BROSSARD, QUEBEC--(Marketwired - March 26, 2015) - Diagnos Inc. ("DIAGNOS" or "the Corporation") (TSX VENTURE:ADK), a leader in healthcare technical services including screening, software and algorithm development, data analysis, and image processing, announced today a renewal of the agreement originally announced on March 14th 2012 that has since been renewed and expanded to a total of fourteen mobile screening units. The value of the two year agreement is approximately 716,000 CAD.

"Since our first announcement of the project in 2012, we have gone from one to fourteen screening units for our global pharmaceutical client, expanding 350% in the last fourteen months alone. Due to such a large growth in the last year, the number of screening units did not increase for this contract renewal, but additional services were added including but not limited to automated image grading with our artificial intelligence engine for 28,000 patients. Our client continues to see a material impact on their business in the UAE and we are very happy that our service is appreciated by the client. Due to our favourable program performance and strong client relationship, we are pursuing materially important leads generated by our client's complimentary referrals to key country-level decision-makers worldwide within the organization, using our project in the UAE as a reference of our success." said André Larente, Diagnos' President.


Founded in 1998, DIAGNOS is a publicly traded Canadian corporation, with a mission to commercialize technologies to improving decision making processes in different sectors. DIAGNOS offers products, services, and solutions to clients in a variety of fields including healthcare and natural resources.

About DIAGNOS Healthcare

DIAGNOS Healthcare is a business division with DIAGNOS Inc., achieving international recognition as leader in healthcare technical services including, screening, software and algorithm development, data analysis, and image processing. Through its Healthcare division, DIAGNOS offers turn-key diabetic retinopathy screening services to patients in various locations around the world.

Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

For further information on DIAGNOS, please visit our website at www.diagnos.com or the SEDAR website at www.sedar.com.

Contact Information

  • Andre Larente
    DIAGNOS Inc.
    (450) 678-8882 ext 224